222 related articles for article (PubMed ID: 30716137)
21. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
[TBL] [Abstract][Full Text] [Related]
22. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J; Ataseven B; Verrill M; De Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X;
Eur J Cancer; 2017 Sep; 82():237-246. PubMed ID: 28625777
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
27. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
Waller CF; Möbius J; Fuentes-Alburo A
Br J Cancer; 2021 Apr; 124(8):1346-1352. PubMed ID: 33589773
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
[TBL] [Abstract][Full Text] [Related]
29. Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong.
Lee VWY; Cheng FWT
Hong Kong Med J; 2023 Feb; 29(1):16-21. PubMed ID: 36731884
[TBL] [Abstract][Full Text] [Related]
30. The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home.
Tjalma W; Huizing MT; Papadimitriou K
Facts Views Vis Obgyn; 2017 Mar; 9(1):51-55. PubMed ID: 28721185
[TBL] [Abstract][Full Text] [Related]
31. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.
McCloskey C; Ortega MT; Nair S; Garcia MJ; Manevy F
Pharmacoecon Open; 2023 Jan; 7(1):3-36. PubMed ID: 35996066
[TBL] [Abstract][Full Text] [Related]
32. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
North RT; Harvey VJ; Cox LC; Ryan SN
Clinicoecon Outcomes Res; 2015; 7():423-30. PubMed ID: 26251623
[TBL] [Abstract][Full Text] [Related]
33. Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden.
Justo N; Wilking N; Jönsson L
Clin Drug Investig; 2023 Jul; 43(7):529-540. PubMed ID: 37422544
[TBL] [Abstract][Full Text] [Related]
34. Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review.
Kolberg HC; Jackisch C; Hurvitz SA; Winstone J; Barham H; Hanes V; Courmier D
Breast; 2021 Jun; 57():95-103. PubMed ID: 33799233
[TBL] [Abstract][Full Text] [Related]
35. Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study.
Abad-Sazatornil MR; Arenaza A; Bayo J; García Mata J; Guinea De Castro JM; León J; Letellez J; Reguero V; Martínez Chamorro C; Salar A
BMC Health Serv Res; 2021 Apr; 21(1):320. PubMed ID: 33832464
[TBL] [Abstract][Full Text] [Related]
36. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.
Papadmitriou K; Trinh XB; Altintas S; Van Dam PA; Huizing MT; Tjalma WA
Facts Views Vis Obgyn; 2015; 7(3):176-80. PubMed ID: 26977267
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
[TBL] [Abstract][Full Text] [Related]
39. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.
Garrison LP; Babigumira JB; Masaquel A; Wang BC; Lalla D; Brammer M
Value Health; 2015 Jun; 18(4):541-6. PubMed ID: 26091608
[TBL] [Abstract][Full Text] [Related]
40. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
